AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan,
which is being developed for the acute treatment of migraine with or without aura in adults.
AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This
study is designed to evaluate the efficacy and safety of AXS-07 compared to meloxicam,
rizatriptan, and placebo for the treatment of a migraine attack.
This is a randomized, double-blind, 4-arm, parallel group, single-dose, placebo-controlled
trial. Subjects who successfully complete screening and continue to meet all entry criteria
will be randomly assigned to take one dose of either AXS-07, meloxicam, rizatriptan, or
placebo upon the occurrence of a qualifying migraine.